Cornell University Presents First Pharmacokinetic  Study on CBD for Dogs

Home/Blogs/Cornell University Presents First Pharmacokinetic  Study on CBD for Dogs

Cornell University Presents First Pharmacokinetic  Study on CBD for Dogs

By |2020-01-06T11:17:40-06:00February 16th, 2018|Blogs|0 Comments

Cannabidiol pet supplements have been steadily growing in popularity over the years.  With all the well-known health benefits for humans, it comes as no surprise that pet owners are choosing cannabidiol (CBD) to treat their beloved animals.  While there has been less research on cannabidiol and pets, many pet parents report it as an effective treatment therapy for issues such as anxiety, arthritis, and epilepsy.

In February 2018, Professor Joseph Wakshlag of Cornell University’s College of Veterinary Medicine conducted the first ever pharmacokinetic study on CBD use in dogs.  The study was to determine how cannabidiol was metabolized, to aim in better determining dosing amounts and frequency. Professor Wakshlag’s study and clinical trial was focused on treating dogs with osteoarthritis and mult-joint pain. Results were summarized that the CBD therapy was “efficacious for pain in dogs with osteoarthritis, chronic joint pain and geriatric pain and soreness; with dramatic beneficial effects in our more geriatric patients.” Over 80% of dogs who received the CBD soft chews saw a significant or dramatic improvement over those taking the placebo.

Research like this helps shine a better light on just how efficacious CBD can be to our furry family members.  Pet owners are excited to be able to offer a natural alternative to pharmaceuticals that treats a variety of pet health issues. There is no doubt that we are only just beginning to learn how cannabidiol can benefit our four-legged family members, and we will continue to see more research on this topic.


To learn more about the study at Cornell University, click here.

About the Author: